OKLAHOMA Health Care Authority | Serving Oklahomans through SoonerCare

December 15, 2025

RE: 2026 Plan Changes Effective January 1, 2026

The following changes will take effect on January 1, 2026. Complete prior authorization (PA) criteria can be found on the OHCA website at www.oklahoma.gov/ohca/pa. Pharmacy PA forms can be found on the OHCA website at www.oklahoma.gov/ohca/rxforms.

Anticoagulants (*OHCA website therapeutic category:* Cardiovascular)

- **Xarelto® (rivaroxaban) 2.5mg tablets and 1mg/mL suspension** will no longer be brand preferred. Members currently utilizing brand Xarelto® 2.5mg tablets or 1mg/mL suspension will need to switch to the generic formulation.

Attention-Deficit Hyperactivity Disorder (ADHD) Medications (*OHCA website therapeutic category:* Central Nervous System/Behavioral Health)

- **Focalin XR® (dexmethylphenidate ER)** will no longer be brand preferred. Members currently utilizing brand Focalin XR® will need to switch to generic dexmethylphenidate ER. The generic formulation will remain in Tier-1.
- **Vyvanse® (lisdexamfetamine) capsules** will be co-preferred (brand or generic) and will remain in Tier-2. Members currently utilizing brand Vyvanse® capsules can fill either the brand or generic formulation going forward.
    - Please note: Since Vyvanse® capsules will no longer be brand preferred, filling the branded product will now count toward member's monthly 2 brand limit.

Diabetes Medications (*OHCA website therapeutic category:* Diabetes/Endocrine)

- **Semglee® (insulin glargine-yfgn)** will be brand preferred, and the Semglee® pen will be preferred over the Semglee® vial.
    - Members currently utilizing the unbranded product will need to switch to branded Semglee®.
    - Members currently utilizing the vials will need to switch to the pens.
- **Synjardy® and Synjardy® XR (empagliflozin/metformin)** will move to Tier-1 and will no longer require a PA.

For a current list of covered **diabetic testing supplies**, please refer to the OHCA website at www.oklahoma.gov/ohca/rx in the Diabetic Supplies section.

Gout Medications (*OHCA website therapeutic category:* Skeletal System)

- **Mitigare® (colchicine) capsules** will no longer be a preferred product. Members currently utilizing colchicine capsules (brand or generic) will need to switch to generic colchicine tablets.

Heart Failure Medications (*OHCA website therapeutic category:* Cardiovascular)

- **Brand Entresto® (sacubitril/valsartan) tablets** will no longer be co-preferred with the generic formulation. Members currently utilizing brand Entresto® tablets will need to switch to generic sacubitril/valsartan.

Targeted Immunomodulator Agents (*OHCA website therapeutic category:* Biologics)

- **Preferred Tier-2 adalimumab products** include branded Hadlima™, unbranded Hulio®, branded Humira®, unbranded Hyrimoz®, branded Simlandi®, and Yusimry®.

Thank you for the service you provide to Oklahomans insured by SoonerCare!